Douglas Jermasek
Fortune : 129 150 $ au 31/05/2026
Fortune : 129 150 $ au 31/05/2026
Douglas Jermasek currently works at Unicycive Therapeutics, Inc., as Executive Vice President-Corporate Strategy from 2021.
Mr. Jermasek also formerly worked at Deltanoid Pharmaceuticals, Inc., as Chief Executive Officer, Keryx Biopharmaceuticals, Inc., as Vice President-Marketing & Strategy from 2016 to 2018, Genzyme Corp., as Senior Vice President & General Manager, and Akebia Therapeutics, Inc., as Senior Vice President-Marketing & Strategy.
Mr. Jermasek received his undergraduate degree from Brigham Young University and Masters Business Admin degree from BYU Marriott School.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/05/2026 | 17 500 ( 0,07% ) | 129 150 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
| KERYX BIOPHARMACEUTICALS | Sales & Marketing | 12/12/2018 |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Corporate Officer/Principal | - |
| AKEBIA THERAPEUTICS, INC. | Sales & Marketing | - |
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops therapies for the treatment of human diseases | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 7 |
|---|---|
Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which focuses on therapies for patients with renal disease | Health Technology |
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Brigham Young University
Brigham Young University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Deltanoid Pharmaceuticals, Inc.
Deltanoid Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops therapies for the treatment of human diseases | Commercial Services |
Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
BYU Marriott School
BYU Marriott School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs to treat kidney diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national